Mizuho Securities analyst Difei Yang maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today and set a price target of $91. The company’s shares opened today at $72.71.
Yang noted:
“We expect the update to be an important catalyst given the large market opportunity in this indication. We expect to see data from three-dose cohorts and a longer follow-up time since the last update at the Hematology (ASH) in December 2017. Management is also advancing preparations for a phase 3 trial in parallel.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.2% and a 50.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $78.25, representing a 7.6% upside.
In a report issued on April 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $103 price target.
Find more picks by Best Performing Analysts >>
The company has a one-year high of $91.75 and a one-year low of $41.06. Currently, Spark Therapeutics has an average volume of 633.5K.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J.
